Oxygen therapy for pulmonary arterial hypertension: We need to rethink and investigate
نویسندگان
چکیده
منابع مشابه
How should we best determine the need for inflight oxygen in patients with pulmonary arterial hypertension?
The British Thoracic Society has recently updated the air travel recommendations suggesting that patients with precapillary pulmonary hypertension (PCPH) in functional classes (FCs) 3 and 4 should have inflight oxygen. This replaces the 2004 recommendations which relied upon baseline oxygen saturation (SpO2) to determine the need for oxygen or to undergo a hypoxic challenge test (HCT). We compa...
متن کاملProstacyclins in pulmonary arterial hypertension: the need for earlier therapy.
Pulmonary arterial hypertension (PAH) is a rare but serious condition, which if untreated, is associated with a 2-3-year median survival time. A number of treatment options are available for PAH, leading to improvements in exercise capacity, symptoms, and hemodynamics. However, the disease remains incurable and most patients will ultimately progress to right heart failure and death. Three class...
متن کاملDo we need controlled clinical trials in pulmonary arterial hypertension?
Uncontrolled studies on the effects of a treatment in a series of patients have a tendency to report favourable results, whereas case reports often inform about adverse effects. Accordingly, the recent publication of an open uncontrolled study reporting favourable effects of an inhaled prostacyclin analogue, iloprost, in patients with primary pulmonary hypertension (PPH) [1], did not come as a ...
متن کاملBeraprost therapy for pulmonary arterial hypertension.
OBJECTIVES The purpose of this study was to assess the safety and efficacy of the oral prostacyclin analogue beraprost sodium during a 12-month double-blind, randomized, placebo-controlled trial in patients with pulmonary arterial hypertension (PAH). BACKGROUND Pulmonary arterial hypertension is a progressive disease that ultimately causes right heart failure and death. Despite the risks from...
متن کاملBosentan therapy for pulmonary arterial hypertension.
BACKGROUND Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Respirology
سال: 2020
ISSN: 1323-7799,1440-1843
DOI: 10.1111/resp.13797